

***MLH1* and *MSH2* mutations in Colombian families with hereditary nonpolyposis colorectal cancer (Lynch syndrome) – description of four novel mutations**

Alejandro Giraldo^{1,2}, Andrea Gómez¹, Gustavo Salguero¹, Herbert García¹, Fabio Aristizábal³, Óscar Gutiérrez¹, Luis Alberto Ángel¹, Jorge Padrón⁴, Carlos Martínez⁵, Humberto Martínez⁶, Omar Malaver⁷, Luis Flórez⁸ and Rosa Barvo⁹

¹*School of Medicine and Genetics Institute, Universidad Nacional de Colombia, Bogotá, Colombia;* ²*Arthur Stanley Gillow Foundation, Bogotá, Colombia;* ³*Department of Pharmacy and Biotechnology Institute, Universidad Nacional de Colombia, Bogotá, Colombia;* ⁴*School of Medicine, Universidad del Rosario, Bogotá, Colombia;* ⁵*Coloproctology Unit, Hospital Militar Central, Bogotá, Colombia;* ⁶*Department of Surgery, Hospital de la Policía, Colombia;* ⁷*Department of Surgery, Clínica San Pedro Claver, Bogotá, ISS, Colombia;* ⁸*Department of Surgery, Hospital de San José, Bogotá, Colombia;* ⁹*Gastroenterology Unit, Clínica La Asunción, Barranquilla, Colombia*

Received 22 October 2004; accepted in revised form 8 March 2005

Key words: Colombian families, familial cancer, HNPCC, Lynch syndrome, *MLH1*, *MSH2*

Abstract

This study searched for mutations in the *MLH1* and *MSH2* genes in 23 unrelated Colombian families with suspected hereditary nonpolyposis colorectal cancer (HNPCC). The families were grouped according to the fulfillment of the Amsterdam II criteria or the Bethesda guidelines. We screened all probands by single-strand conformational polymorphism (SSCP) and direct DNA sequencing. Eleven families fulfilled the Amsterdam criteria II and 12 families the Bethesda guidelines. Germline mutations were detected in 11 families, which corresponds to a mutation detection rate of 48%. When only families fulfilling the Amsterdam II criteria were analyzed, the mutation detection rate rose to 82%. Only 8% of the mutation detection rate was found in families following the Bethesda guidelines. Three mutations were shared by two different families, which corresponds to a total of eight different mutations, seven of them found in the *MLH1* gene and one in the *MSH2* gene. We have identified four mutations that have not been previously reported to the International Collaborative Group of HNPCC. Three of these are pathogenic, a single base substitution (C > T) at codon 640, exon 17, a G deletion at codon 619, exon 16 and in the *MLH1* gene and a two-nucleotide deletion (TG) at codon 184, exon 3 in the *MSH2*. Also, an unclassified variant, a substitution (C > G) at the codon 141, exon 5 of the *MLH1*, was detected.

Introduction

Colorectal cancer (CRC) is the second leading cause of cancer death in the developed world, while in developing countries it is the sixth or seventh cause of death, although these last figures are quite heterogeneous and differ racially and by gender [1, 2]. It has been estimated in the US, that 56,730 CRC-specific deaths will occur in the year 2004 [3]. In Colombia, CRC is the fifth cause of cancer mortality and it is estimated that approximately 1500 individuals die annually due to CRC [4, 5]. From 3 to 5% of the total colorectal cancer cases correspond to hereditary nonpolyposis colorectal cancer (HNPCC) or

Lynch syndrome. This is a cancer predisposition syndrome inherited in an autosomal dominant fashion [6], with high penetrance (85%) and variable expressivity. Besides CRC, other cancers are also common in HNPCC, as endometrial, small-bowel, ureter and renal pelvis carcinoma, and to a lesser extent, stomach, ovary and hepatobiliary carcinoma. It is estimated that up to 75 persons die annually in Colombia due to this autosomal dominant inherited disease.

Colon cancers from patients with HNPCC are characterized by expansion or contraction of short repeat sequences of DNA (microsatellite) at multiple loci. The cause of this phenomenon, known as microsatellite

instability (MSI), is thought to be responsible for the rapid accumulation of somatic mutations in oncogenes and tumor-suppressor genes that play crucial roles in the initiation and progression of tumors, mainly those with nucleotide repetitions in its coding segments [7]. This instability is due to germline mutations in, at least, 5 DNA mismatch-repair genes (MMR) genes (*MLH1*, *MSH2*, *MSH6*, *PMS1* and *PMS2*). The great majority of germline mutations are found in *MLH1* and *MSH2*, while mutations in the other 3 MMR genes have been reported only in a limited number of cases. Carriers of germline MMR mutations have a >80% risk of cancer by the age of 75. Mutations in MMR genes result in MSI, which is characteristic of >90% of tumors from HNPCC patients and approximately 12% of sporadic colorectal tumors [7, 8].

Like any other cancer, CRC is preventable if detected at an early stage and several strategies have been proposed for this purpose. For the purpose of clinical diagnosis, several criteria were proposed in 1991, and afterwards revised, which are currently known as Amsterdam-II criteria [9]. Additionally, the Bethesda guidelines were proposed, not only for clinical purposes but also for defining the suitability for MSI analysis. These criteria have recently been revised [10]. MSI have been proposed to be tested in CRC tissues and those showing instability, and without promoter methylation, being subsequently sequenced [11, 12].

The aim of this study was to identify mutations in the two major susceptibility genes *MLH1* and *MSH2*, in 23 unrelated Colombian families with suspected HNPCC, by means of single-strand conformational polymorphism (SSCP) and subsequent sequencing of the fragments that displayed an abnormal pattern.

Materials and methods

All aspects of this study were reviewed and approved by the Ethics Committee of the School of Medicine of the Universidad Nacional de Colombia.

Families and patients

Families were searched through proctologic services of different hospitals of Bogotá and Barranquilla, and in the files of clinical and surgical gastroenterologists. All were traditional Colombian families without any recent immigrant ancestors. We classified pedigrees of 23 families by whether they fulfilled the Amsterdam II or followed the Bethesda guidelines. Informed consent was obtained from each participant. Personal and family cancer histories were obtained from the proband and participating relatives, and cancer diagnoses and deaths were confirmed by reviewing the medical records or pathology reports.

DNA analysis

Blood samples were obtained from one or two cancer syndrome affected members from each family. Genomic

DNA was isolated from peripheral blood lymphocytes according to the salting out procedure [13]. The entire *MLH1* and *MSH2* coding region and the splice junctions were amplified by PCR from genomic DNA using 19 and 16 primer pairs, respectively, according to reported primers [14], with some modifications for exon 10 of *MLH1* and exons 1 and 11 of *MLH2* genes. Primer sequences modifications are available upon request.

All amplicons were subjected to SSCP [15] and the DNA fragments that displayed an abnormal pattern were analyzed by cycle sequencing with the ABI Prism dRhodamine Terminator Sequencing Kit and analyzed in the ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA). All mutations were confirmed by two independent sequencing PCRs and sequenced in both directions.

Bioinformatic analysis procedure

For the mutation analysis of family UN-04 and UN-23, Pfam database and UniProt [16, 17] were used to search for the correspondent domains for the 640 and 141 *MLH1* amino acids. Matching sequences were aligned and appointed with ClustalW and Clustal X [18, 19].

Results

Of the 23 families, 11 fulfilled the Amsterdam criteria II, and 12 families fulfilled the Bethesda guidelines. Germline mutations were detected in 11 families, which corresponds to a mutation detection rate of 48%. When only families fulfilling Amsterdam criteria were analyzed, the mutation detection rate rose to 82%. On the other hand, only 8% (1/12) of the mutation detection rate was found in families fulfilling the Bethesda guidelines. Out of the detected mutations in the 11 families, three mutations were shared by two different families, which corresponds to a total of eight different mutations, seven of them found in the *MLH1* gene and one in the *MSH2* gene (Table 1).

We have identified four mutations that have not been previously reported to the International Collaborative Group of HNPCC (www.nfdht.nl). Three of mutations are in the *MLH1* gene. These are a single base substitution (C > T) at codon 640, exon 17 (pathogenic, Family UN-4), a G deletion at codon 619, exon 16 (pathogenic, Families UN-21 and UN-23) and a substitution (C > G) at the codon 141, exon 5 (unclassified variant, Family 23). In the *MSH2* gene, a two-nucleotide deletion (TG) at codon 184, exon 3 was detected (pathogenic, family, UN-2). (Table 1, Figure 1.)

Discussion

The racial admixture among aboriginal populations, Spaniard colonist and African slaves resulted in the Colombian population, mainly during the 17th and 18th

Table 1. Mutations at the *MLH1* and *MSH2* genes in Colombian families.

Family	Criteria	Gene	Exon	Position	Nucleotide change	Consequence	Reported
UN-1	Amsterdam II	<i>MLH1</i>	9	790 + 1	G > A	Splicing defect	Yes
UN-6	Amsterdam II	<i>MLH1</i>	9	790 + 1	G > A	Splicing defect	Yes
UN-8	Amsterdam II	<i>MLH1</i>	13	1558 + 14	G > A	None	Yes
UN-17	Bethesda	<i>MLH1</i>	13	1558 + 14	G > A	None	Yes
UN-4	Amsterdam II	<i>MLH1</i>	17	1918	C > T	Proline/Serine	New
UN-16	Amsterdam II	<i>MLH1</i>	17	1964	A > G	Isoleucine/Valine	Yes
UN-3	Amsterdam II	<i>MLH1</i>	18	2041	G > A	Alanine/Threonine	Yes
UN-21	Amsterdam II	<i>MLH1</i>	16	1856	del G	Frameshift/Stop	New
UN-23	Amsterdam II	<i>MLH1</i>	16	1856	del G	Frameshift/Stop	New
UN-23	Amsterdam II	<i>MLH1</i>	5	421	C > G	Proline/Alanine	New
UN-2	Amsterdam II	<i>MSH2</i>	3	596	del TG	Frameshift/Stop	New

century. Immigrations at the end of the 19th century or during the 20th century, from European or Middle East countries, were remarkably lower than those in other

South American countries. For that reason, it is highly unusual to trace back a recent ancestor out of Colombia for the vast majority of the families. None of our studied




Figure 1. SSCP and nucleotide sequences of four new mutations, a and b, Family UN-04. (a) SSCP analysis of exon 17 of the hMLH1. Lane 1 shows abnormal mobility. (b) Nucleotide sequence of exon 17; the arrowheads show the mutation sites. c and d, families UN-21 and UN-23. (c) SSCP analysis of exon 16 of the hMLH1; Lane 3 shows abnormal mobility. (d) Nucleotide sequence of exon 16; the arrowheads show the G:C deletion in both strands. e and f, Family 23. (e) SSCP analysis of exon 5 of the hMLH1; Lane 2 shows abnormal mobility. (f) Nucleotide sequence of exon 5; the arrowheads show the mutation site. g and h, family UN-2. (g) The upper panel shows a PAGE at the 14%; Lanes 5 and 8, both of exon 3 of the *MSH2* gene, show two additional bands in PCR fragments. The lower panel shows a normal SSCP analysis of exon 3. (h) Nucleotide sequence of exon 3 of the *MSH2*; the arrowheads show the deletion in both strands.

families has any recent European or non-European ancestors, which is similar to that observed in Brazil [20], but in contrast to NHPCC families from Uruguay [21].

Ethnic variations in both the prevalence of the HNPCC phenotype and carrier frequencies of germline *MLH1* and *MSH2* mutations in selected HNPCC families have been extensively described, mainly in Europe and in the USA [22–26]. There are no previous studies of mutations of *MLH1* or *MSH2* genes in Colombia. This work, therefore, represents the first record of such mutations in Colombian patients with HNPCC and one of the few in Latin America.

Twenty-three unrelated families were studied and germline mutations were detected in 11 families, which corresponds to a detection rate of 48%, which is similar to that observed in several studies, when Amsterdam criteria and Bethesda guidelines are considered together [20, 26]. When only the Amsterdam criteria are considered, the detection rate increases to 82%, which is similar to the rate observed in other studies, when these criteria are exclusively considered [23]. However, these figures vary widely [22–26]. The differences in detection rate could be due to random variation, or population substructure in European older populations, or in Latino American, newer and more heterogeneous or mixed populations.

Of the four new mutations detected, three are predicted to be pathogenic. Observed in Families UN-21 and UN-23, is a nucleotide deletion (delG) in the exon 16, position 1856 of the *MLH1* gene that produces a frame shift and a stop codon. The same consequence produces the two nucleotide deletion (delTG) in the *MSH2* gene observed in family UN-2.

The third predicted pathogenic mutation is observed in the *MLH1* gene of family UN-4. This missense C > T transition in the exon 17, position 1918, causes

in the amino acid 640 a proline substitution to serine, an amino acid of different polarity (Figure 2). Proline, a small aliphatic amino acid with a rigid heterocyclic structure, is conserved in this position among eukaryotic species (yeasts, nematodes, plants and mammals) and also in *E. coli*. In addition, proline is involved in the formation of alpha helices and bends, and the presence of another highly conserved proline eight positions downstream may represent a group of cyclic folding, which could be essential for the protein structure. The high level of conservation of codon for proline 640 of the *MLH1* gene suggests that a mutation that changes this amino acid for a substantially different one might have a remarkable impact on the function and transportation of the protein. Additionally, in this family the mutation co-segregates with the disease in three affected members of the same sibship. Two healthy sibs, 53 and 51 years old were not available for study. The mutation is not present in a healthy 42-year-old woman, but a healthy 35-year-old woman is a mutation carrier. This mutation was not searched in the normal population.

Additionally, in family UN-23, but not in family UN-21 (these two families share a pathogenic mutation in the exon 16 of *MLH1* gene), a missense (C > G) transversion in the exon 5, position 421, was detected in the same *MLH1* gene. This mutation produces a change in amino acid 141, proline to alanine (Figure 3). Both are aliphatic apolar amino acids with chains that can be considered equivalent in relation to their small molecular volumes. The analysis of the three-dimensional structure of MLH1 protein indicates that this position corresponds to a large size linker between the ATPase and the DNA repair domains [27–30]. Notwithstanding, the necessary interaction between these two domains, the change of the amino acid 141 would not produce important modifications because the amino acid in this

MLH1 nucleotide sequence, exon 17, position 1918
Homo sapiens ATTGGATTACCCCTTCTGATTGACAACACTATGTGCCCCCTTT
Mus musculus ATTGGATTACCTCTTCTGATTGACAGCTATGTGCCACCTTT
S. cerevisiae AAATCTCTACCACTACTTTTAAAAGGCTACATTCCATCTCT
 Family UN-04 ATTGGATTATCCCTTCTGATTGACAACACTATGTGCCCCCTTT

MLH1 amino acid sequence (amino acid 640 shadowed)
Homo sapiens DEEGLNIGLPLLLIDNYVPPLEGLPIFILRL
Mus musculus DEEGLNIGLPLLLIDS YVPPLEGLPIFILRL
 Family UN-04 DEEGLNIGLLSLLIDNYVPPLEGLPIFILRL

Figure 2. Nucleotide sequence of a segment of exón 17 and relative position of amino acid 640 of *MLH1* gene.

MLH1 nucleotide sequence, exon 5, position 421
Homo sapiens CCTCCTAAACCATGTGCTGGCAATCAAGGGACCCAGATCACGGTG
Mus musculus CCTCCTAAACCCTGTGTCAGGCAACCAGGGACCCCTGATCACGGTG
S. cerevisiae AGCCCCAAACCTGTTGCTGGAAAAGACGGTACCACGATCCTAGTT
 Family UN-23 CCTCCTAAAGCATGTGCTGGCAATCAAGGGACCCAGATCACGGTG

MLH1 amino acid sequence (amino acid 141 shadowed)
Homo sapiens PPKPCAGNQGLITV
Mus musculus PPKPCAGNQGLISV
 Family UN-23 PPKACAGNQGLITV

Figure 3. Nucleotide sequence of a segment of exón 5 and relative position of amino acid 141 of *MLH1* gene.

position seems to be involved in a β sheet formation, in which the Van der Waals interactions are still functioning as far as no relevant modification in the molecular volume or in the polarity of the amino acids are given. Compound heterozygosity for two different MLH1 missense mutations has been described, apparently without a highly increased risk of colon cancer [31]. On the other hand, individuals homozygous for pathogenic mutations are expected to display signs of neurofibromatosis type 1 and to develop hematological malignancies early in life [32–34]. Our compound heterozygous patient from family UN-23 is a 45-year-old female with only CRC to date. Notwithstanding the previous considerations, this mutation should be considered an unclassified variant.

The three families sharing the same mutations (UN-1 and UN-6; UN-8 and UN-17, and UN-21 and UN-23), did not know each other, although they came from neighboring regions. A founder effect of these three mutations is to be confirmed, as has been done for the confirmed founder effect for both *MLH1* and *MSH2* genes in several European countries and in USA [35–39].

With regard to the proportion of mutations in *MLH1* and *MSH2* genes, this also varies according to different studies. As in our case, the Brazilian study observed a major frequency of mutations in the *MLH1* gene [16]; a similar proportion has been observed in the Korean population [40]. However, an inverse proportion has been observed in several other studies [41], or similar proportions in both genes [42, 43].

In conclusion, it is clear that identifying HNPCC families and carriers presents a life-saving potential through early cancer detection. We suggest that not only HNPCC families fulfilling the Amsterdam criteria, but also those following the Bethesda guidelines should undergo genetic testing. Identification of the pathogenic mutations would greatly facilitate presymptomatic diagnoses useful in genetic counseling, making therapeutic decisions and developing protocols to implement clinical surveillance of the established carriers prior to disease manifestation.

Acknowledgements

We sincerely thank the families for participating in this study and the many clinicians who were willing to cooperate. We also thank Dr Henry T. Lynch, Dr Miguel Rodríguez-Bigas and Ms Peggy Conrad for their advice and support in the initial steps of this research, when we had the great opportunity to meet them in our country. This research was granted by the contract Colciencias-Universidad Nacional de Colombia No. 114-2000.

References

- Peto J. Cancer epidemiology in the last century and the next decade. *Nature* 2001; 411: 390–5.
- Anderson WF, Umar A, Brawley OW. Colorectal carcinoma in black and white race. *Cancer Metastasis Rev* 2003; 22: 67–82.
- Jemal A, Tiwari RC, Murray T. Cancer statistics, 2004CA. *Cancer J Clin* 2004; 54: 8–29.
- Angel LA, Giraldo A, Pardo CE. Mortalidad por cánceres del aparato digestivo en Colombia entre 1980 y 1998. Análisis de tendencias y comparación regional. *Rev Fac Medicina (Universidad Nacional de Colombia)* 2004; 52: 19–37.
- GLOBOCAN. Cancer Incidence, Mortality and Prevalence Worldwide. <http://www-dep.iarc.fr/globocan/globocan.html> 2000.
- Lynch HT, la Chapelle Ade. Genetic susceptibility to non-polyposis colorectal cancer. *J Med Genet* 1999; 36: 801–18.
- Wijnen JT, Vasen HF, Khan PM. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. *N Engl J Med* 1998; 339: 511–8.
- Aaltonen LA, Salovaara R, Kristo P. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. *N Engl J Med* 1998; 338: 1481–7.
- Vasen HFA, Watson P, Mecklin JP. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch Syndrome) proposed by the International Collaborative Group on HNPCC. *Gastroenterology* 1999; 116: 1453–6.
- Umar A, Boland CR, Terdiman JP. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004; 96: 261–8.
- de la Chapelle A. Inherited human diseases: Victories, challenges, disappointments. *Am J Hum Genet* 2003; 72: 236–40.
- Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary non-polyposis colorectal cancer. *Genet Med* 2003; 5: 353–63.
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acid Res* 1988; 16: 1215.
- Weber TK, Conlon W, Petrelli NJ. Genomic DNA-based hMSH2 and hMLH1 mutation screening in 32 Eastern United States hereditary nonpolyposis colorectal cancer pedigrees. *Cancer Res* 1997; 57: 3798–3803.
- Beck NE, Tomlinson IP, Homfray T. Use of SSCP analysis to identify germline mutations in HNPCC families fulfilling the Amsterdam criteria. *Hum Genet* 1997; 99: 219–24.
- Bateman A, Coin L, Durbin R. The Pfam protein families database. *Nucleic Acids Res* 2004; 32: D138–41.
- Apweiler R, Bairoch A, Wu CH. UniProt: The universal protein knowledgebase. *Nucleic Acids Res* 2004; 32: D115–9.
- Yuan J, Amend A, Borkowski J. MULTICLUSTAL: A systematic method for surveying Clustal W alignment parameters. *Bioinformatics* 1999; 15: 862–3.
- Thompson JD, Gibson TJ, Plewniak F. The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. *Nucleic Acids Res* 1997; 25: 4876–82.
- Rossi BM, Lopes A, Oliveira Ferreira F. hMLH1 and hMSH2 gene mutation in Brazilian families with suspected hereditary nonpolyposis colorectal cancer. *Ann Surg Oncol* 2002; 9: 555–61.
- Sarroca C, Peltomäki P, Alfano N. Three new mutations in hereditary nonpolyposis colorectal cancer (Lynch syndrome II) in Uruguay. *Cancer Genet Cytogenet* 2003; 142: 13–20.
- Tannergard P, Lipford JR, Kolodner R. Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis colon cancer families. *Cancer Res* 1995; 55: 6092–6.
- Nystrom-Lahti M, Wu Y, Moisio AL. DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary nonpolyposis colorectal cancer. *Hum Mol Genet* 1996; 5: 763–9.
- Viel A, Genuardi M, Capozzi E. Characterization of MSH2 and MLH1 mutations in Italian families with hereditary nonpolyposis colorectal cancer. *Genes Chromosom Cancer* 1997; 18: 8–18.
- Lynch HT, Watson P, Shaw TG. Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer, Part I: Studies of cancer in families. *Cancer* 1999; 86: 2449–56.

26. Caldes T, Godino J, de la Hoya M. Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain. *Int J Cancer* 2002; 98: 774–9.
27. Ban C, Yang W. Crystal structure and ATPase activity of MutL: Implications for DNA repair and mutagenesis. *Cell* 1998; 95: 541–52.
28. Ban C, Junop M, Yang W. Transformation of MutL by ATP binding and hydrolysis: A switch in DNA mismatch repair. *Cell* 1999; 97: 85–97.
29. Prodromou C, Panaretou B, Chohan S. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. *EMBO J*. 2000; 19: 4383–92.
30. Brino L, Urzhumtsev A, Mousli M. Dimerization of *Escherichia coli* DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center. *J Biol Chem* 2000; 275: 9468–75.
31. Hackman P, Tannergard P, Osei-Mensa S. A human compound heterozygote for two MLH1 missense mutations. *Nat Genet* 1997; 17: 135–6.
32. Wang Q, Lasset C, Desseigne F. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. *Cancer Res* 1999; 59: 294–7.
33. Ricciardone MD, Ozcelik T, Cevher B. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. *Cancer Res* 1999; 59: 290–3ç.
34. Vilkki S, Tsao JL, Loukola A. Extensive somatic microsatellite mutations in normal human tissue. *Cancer Res* 2001; 61: 4541–4.
35. Nystrom-Lahti M, Sistonen P, Mecklin JP. Close linkage to chromosome 3p and conservation of ancestral founding haplotype in hereditary nonpolyposis colorectal cancer families. *Proc Natl Acad Sci USA* 1994; 91: 6054–8.
36. Moisio AL, Sistonen P, Weissenbach J. Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer. *Am J Hum Genet* 1996; 59: 1243–51.
37. Hutter P, Couturier A, Membrez V. Excess of hMLH1 germline mutations in Swiss families with hereditary non-polyposis colorectal cancer. *Int J Cancer* 1998; 78: 680–4.
38. Wagner A, Barrows A, Wijnen JT. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. *Am J Hum Genet* 2003; 72: 1088–1100.
39. Lynch HT, Coronel SM, Okimoto R. A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. *JAMA* 2004; 291: 718–24.
40. Han HJ, Yuan Y, Ku JL. Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary nonpolyposis colorectal cancer. *J Natl Cancer Inst* 1996; 88: 1317–9.
41. Bai YQ, Akiyama Y, Nagasaki H. Predominant germ-line mutation of the hMSH2 gene in Japanese hereditary non-polyposis colorectal cancer kindreds. *Int J Cancer* 1999; 82: 512–5.
42. Wang Q, Lasset C, Desseigne F. Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer. *Hum Genet* 1999; 105: 79–85.
43. Taylor CF, Charlton RS, Burn J. Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA. *Hum Mut* 2003; 22: 428–33.

Copyright of *Familial Cancer* is the property of Springer Science & Business Media B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.